SilcsBio | Visualizing Computer-Aided Drug Design

Visualize Drug Design in a Whole New Way

SilcsBio provides computer-aided drug design solutions that dramatically accelerate and improve small molecule and biologic drug discovery pipelines..

Learn More

SilcsBio Response to Covid-19

SilcsBio has created a FragMap library of many of the proteins of the Covid-19 virus to drive your drug discovery efforts.

Covid-19 Main Protease FragMap

The SilcsBio Difference

Services

Our experts provide consultation and training, paired with guided deployment of the SILCS platform technology, to enable drug discovery teams to work faster and more productively.

Software

Patented SILCS technology works in tandem with SILCS-Biologics, CGenFF, and SSFEP for targeted solutions or complete end-to-end drug design workflow — from hit identification to lead optimization.

Platform

Our proprietary CADD software technology, SILCS, allows researchers to visualize and interact with 3D maps of protein surfaces for drug design.

SILCS

Site-Identification by Ligand Competitive Saturation

Our proprietary CADD software technology, SILCS, generates highly accurate 3D free energy maps called “FragMaps” which account for conformational nuances to reveal hidden pockets of opportunity.

SILCS FragMaps technology gives you an intuitive way of interacting with and visualizing the entire protein surface, further enabling your drug discovery team to:

Accelerate drug discovery timelines
Enhance high throughput screening to drive hit selection
Reduce drug development costs
Bolster drug development pipelines

View Demo

Why SilcsBio outperforms all others

SILCS is built on rigorous free energy calculations employing:

Multiple small molecule probes with diverse functional groups
Explicit solvent modeling
Target molecule flexibility
Advanced sampling methods (GCMC/MD) to identify cryptic pockets

The proof is in the details

Publications

Our Team

Our team is committed to delivering the fastest, most reliable drug designs for your highest value drug programs. We are committed to providing our expertise and technology to unlock a whole new world of possibilities for you and your team.

Meet Our Team

Our Partners and Collaborators

SilcsBio and Dalriada Drug Discovery Launch Partnership to Create a Rapid Drug Discovery Service Suite

SilcsBio and Dalriada to tap areas of expertise in drug design and development to accelerate clients’ programs in development of therapeutic treatments against diseases with unmet needs, initiated with COVID-19 FOR IMMEDIATE RELEASE: June 11, 2020, Baltimore, MD and Toronto, ON – SilcsBio, a technology company that develops innovative software and provides services for structure-based […]

FOR IMMEDIATE RELEASE: SilcsBio Joins with NIST and Pharma Partner In Validating SILCS Technology for Biologics Formulation Scientific collaboration demonstrates effective computational method for stabilizing biologic therapeutics such as antibodies December 16, 2020, Baltimore, MD – SilcsBio, LLC, a technology company that develops and markets software and services for structure-based drug design, today announced members […]

GEn1E Lifesciences, a Y Combinator-Backed Company, Granted Exclusive License for University of Maryland, Baltimore Drug Portfolio Compound Tuesday, December 3, 2019 PALO ALTO, Calif. and BALTIMORE, Dec. 3, 2019 /PRNewswire/ — GEn1E Lifesciences Inc., a Y Combinator-backed biotech startup focused on curing inflammatory and age-related diseases, announced today that it has acquired an exclusive, worldwide and […]